Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 19/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438420 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8590069 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9048729 | 0.94 | ALOX5 (0.88) | ALOX5EPHX2 | |
| SCHEMBL12420450 | 0.91 | ALOX5 (0.83) | ALOX5EPHX2 | |
| SCHEMBL13140099 | 0.91 | ALOX5 (0.83) | ALOX5EPHX2 | |
| SCHEMBL9047929 | 0.90 | ALOX5 (0.81) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9047669 | 0.90 | ALOX5 (0.81) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9049110 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9049256 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9047887 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1947942-B1 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2015-07-29 | — | — | EP | claimed |
| US-8980918-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | claimed |
| US-8703956-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-04-22 | — | — | US | claimed |
| CN-101277614-A | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway | ACCELALOX INC (US) | 2008-10-01 | — | — | CN | claimed |
| EP-1947942-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | Accelalox, Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007022427-A9 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2007022427-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| EP-0731688-B1 | AEROSOL DRUG FORMULATIONS FOR USE WITH NON-CFC PROPELLANTS | ABBOTT LAB (US) | 2003-03-05 | — | — | EP | claimed |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. | 2002-10-03 | — | — | US | claimed |
| EP-0888127-B1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2001-12-12 | — | — | EP | claimed |
| US-6136839-A | USING A SULFONE OR SULFOAMIDE BENZENE COMPOUND | G. D. SEARLE & CO. (US) | 2000-10-24 | — | — | US | claimed |
| WO-1998058644-A1 | (S)-(-)-N-[3- [5-(4-FLUOROPHENOXY) -2-FURANYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | claimed |
| US-5676931-A | DRUG DELIVERY | ABBOTT LABORATORIES (US) | 1997-10-14 | — | — | US | claimed |
| EP-0540673-B1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1996-10-16 | — | — | EP | claimed |
| US-5559144-A | LIPOXYGENASE INHIBITORS, INHIBITORS OF BIOSYNTHESIS OF LEUKOTRIENES | ABBOTT LABORATORIES (US) | 1996-09-24 | — | — | US | claimed |
| EP-0540673-A4 | — | — | 1994-04-27 | — | — | EP | claimed |
| EP-0540673-A1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001682-A1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | ALOX5, ALOX15B, ALOX15 | ALOX5 1/4885EPHX2 99/4885ACACB 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.